To assess changes in activities of daily living per muscle subdomain in patients with generalized myasthenia gravis (gMG) treated with the complement C5 inhibitor eculizumab in clinical practice.
No takes yet. Share an insight, caveat, or question.
Juel et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: